User profiles for Y. Bennani

Younès Bennani

Full Professor, Université Sorbonne Paris Nord
Verified email at lipn.univ-paris13.fr
Cited by 2985

trans-1,2-Diaminocyclohexane Derivatives as Chiral Reagents, Scaffolds, and Ligands for Catalysis:  Applications in Asymmetric Synthesis and Molecular …

YL Bennani, S Hanessian - Chemical reviews, 1997 - ACS Publications
Asymmetric synthesis has witnessed a burgeoning activity in the discovery, development, and
application of numerous methods for the creation of stereogenic centers with high levels of …

The osmium-catalyzed asymmetric dihydroxylation: a new ligand class and a process improvement

KB Sharpless, W Amberg, YL Bennani… - The Journal of …, 1992 - ACS Publications
Bennani, Gerard A. Crispino, Jens Hartung, Kyu-Sung Jeong, Hoi-Lun Kwong, Kouhei
Morikawa, Zhi-Min Wang, Daqiang Xu, and Xiu-Lian Zhang … (h) Ogino, Y.; Chen, H.; …

Natural products in medicine: transformational outcome of synthetic chemistry

…, JF Truchon, YL Bennani - Journal of medicinal …, 2014 - ACS Publications
This review brings to the forefront key synthetic modifications on natural products (NPs) that
have yielded successful drugs. The emphasis is placed on the power of targeted chemical …

Drug discovery in the next decade: innovation needed ASAP

YL Bennani - Drug Discovery Today, 2011 - Elsevier
Pharmaceutical companies must find a better way to increase their output of truly new drugs
for the benefit of patients and for their business survival. Here, I highlight a general …

Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl] ethyl}-benzofuran-5-yl) benzonitrile]: II. Neurophysiological characterization and broad …

…, K Marsh, M Lemaire, RD Porsolt, YL Bennani… - … of Pharmacology and …, 2005 - ASPET
Acute pharmacological blockade of central histamine H 3 receptors (H 3 Rs) enhances
arousal/attention in rodents. However, there is little information available for other behavioral …

Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2

…, Y Zhang, FG Salituro, YL Bennani… - Journal of medicinal …, 2014 - ACS Publications
In our effort to develop agents for the treatment of influenza, a phenotypic screening approach
utilizing a cell protection assay identified a series of azaindole based inhibitors of the cap-…

A survey on domain adaptation theory: learning bounds and theoretical guarantees

…, E Morvant, A Habrard, M Sebban, Y Bennani - arXiv preprint arXiv …, 2020 - arxiv.org
… We assume that X × Y is drawn from an unknown joint probability distribution D and that
we observe them through a finite training sample (also called the learning sample) S = {(xi,yi)}m …

In vitro and in vivo isotope effects with hepatitis C protease inhibitors: enhanced plasma exposure of deuterated telaprevir versus telaprevir in rats

…, S Raybuck, M Namchuk, YL Bennani - Journal of medicinal …, 2009 - ACS Publications
Telaprevir 2 (VX-950), an inhibitor of the hepatitis C virus (HCV a ) NS3-4A protease, is in
phase 3 clinical trials. One of the major metabolites of 2 is its P1-(R)-diastereoisomer, 3 (VRT-…

Rapamycin and Less Immunosuppressive Analogs Are Toxic to Candida albicans and Cryptococcus neoformans via FKBP12-Dependent Inhibition of TOR

…, JR Perfect, JH McCusker, YL Bennani… - Antimicrobial agents …, 2001 - Am Soc Microbiol
Candida albicans and Cryptococcus neoformans cause both superficial and disseminated
infections in humans. Current antifungal therapies for deep-seated infections are limited to …

[BOOK][B] Advances in domain adaptation theory

I Redko, E Morvant, A Habrard, M Sebban, Y Bennani - 2019 - books.google.com
… We note that depending on the application, both X and Y can be defined in … Y and assuming
that there is an unknown joint probability distribution D defined on their product space X × Y